By MOS Medical Group — Eglise Bell

The World Health Organization (WHO), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have repeatedly suggested that no antiviral treatments exist for covid-19, even though multiple antiviral drugs have been studied during previous SARS and MERS epidemics and found to be effective. As a result, many patients in the U.S. still struggle to access the drug, as many doctors are unwilling to prescribe it off-label against health officials’ recommendations. 

As Hydroxychloroquine (HCQ), the drug was approved by FDA in 1955 to treat and prevent malaria, also prescribed for lupus and rheumatoid arthritis, was revoked from the Emergency Use Authorization (EUA, issued in March 2020) to treat COVID-19 by FDA on June 15, 2020, because data suggested it “unlikely to be effective in treating COVID-19” and that its potential risks outweighed the benefits. Yet, a recent study has found that the use of weight-adjusted HCQ and azithromycin (AZM) improved the survival of ventilated COVID-19 patients by nearly 200%.

Recently, another clinically proved to be effective to treat COVID-19 drug, Ivermectin, met the similar obstacles as HCQ. What makes ivermectin particularly useful in COVID-19 is the fact that it works both in the initial viral phase of the illness, when antivirals are required, as well as the inflammatory stage, when the viral load drops off and anti-inflammatories become necessary.

According to Dr. Surya Kant, a medical doctor in India who has written a white paper on ivermectin, and an Australian research group reported that a single use of Ivermectin reduces replication of the SARS-CoV-2 virus by more than 5000 thousand times at 48 h in vitro. Their research findings led several Indian provinces to start using ivermectin, both as a prophylactic and as treatment for COVID-19 in the summer of 2020.

In late of 2020, a scientific review by Dr. Andrew Hill at Liverpool University, funded by the WHO and UNITAID and published January 18, 2021, found ivermectin reduced COVID-19 deaths by 75%. It also increased viral clearance. This finding was based on a review of six randomized, controlled trials involving a total of 1,255 patients.

Dr. Tess Lawrie, the Director of The Evidence-based Medicine Consultancy Ltd and CEO of EbMCsquared [Bath, UK] did meta-analysis, published February 8, 2021, found a 68% reduction in deaths. 13 studies were included in the analysis. It is an underestimation of the beneficial effect because they included a study in which the control arm was given HCQ. Since HCQ is an active treatment that has also been shown to have a positive impact on outcomes, it is not surprising that this particular study did not rate ivermectin as better than the control treatment (which was HCQ).

Adding two new randomized controlled trials to her February analysis that included data on mortality, Lawrie published an updated analysis March 31, 2021, showing a 62% reduction in deaths. When four studies with high risk of bias were removed during a subsequent sensitivity analysis, they ended up with a 72% reduction in deaths. Sensitivity analyses are done to double-check and verify results.

Numerous clinical studies — including peer-reviewed randomized controlled trials — showed large magnitude benefits of Ivermectin in prophylaxis, early treatment and in late-stage disease. Taken together … dozens of clinical trials that have now emerged from around the world are substantial enough to reliably assess clinical efficacy.

How Ivermectin works?

Ivermectin, is a simple anti-parasite medicine derived from the bacterium Streptomyces avermitilis. It is FDA-approved for parasitic infections, and therefore has a potential for repurposing. In fact, it has shown great efficacy in the fight against CCP virus. And it is widely available, due to its inclusion on the WHO model list of essential medicines.

For the first time, medical researchers have documented how ivermectin docks to the SARS-CoV-2 spike receptor-binding domain that is attached to the Angiotensin-Converting Enzyme 2 (ACE2) receptor. In this way, ivermectin effectively inhibits viral attachment and replication, assisting a precise antiviral response that can target the SARS-CoV-2 spike protein at its most advantageous cleavage site. The researchers showed how ivermectin interferes with the attachment of the spike protein to the human cell membrane.

The SARS-CoV-2 spike protein is designed to attach to ACE2 in humans. To see whether ivermectin could dock at this receptor site and block viral attachment, the researchers used a program called AutoDock Vina Extended. This docking study showed the crystal structure of the SARS-CoV-2 spike receptor binding domain. The researchers looked specifically at the human ACE2 receptor and calculated the root-mean-square deviation (RMSD) of its atomic positions. A lower RMSD value indicates a more accurate docking capacity. When the RMSD value is three or greater, no docking has occurred at the receptor site. Ivermectin did not dock at nine of the locations; however, it did dock at the leucine 91 region of the spike and histidine 378 at the intersection of proteins between SARS CoV-2 and the ACE2 receptor complex. The binding energy and constancy of ivermectin was also measured and found to be sufficient at the ACE2 receptor, proving the anti-parasitic molecule a powerful force for blocking viral attachment of SARS-CoV-2.

Doctors Urge Acceptance of Ivermectin to Save Lives

The Frontline COVID-19 Critical Care Alliance (FLCCC) president Dr. Pierre Kory, former professor of medicine at St. Luke’s Aurora Medical Center in Milwaukee, Wisconsin, has testified to the benefits of ivermectin before several COVID-19 panels, including the Senate Committee on Homeland Security and Governmental Affairs in December 2020, and NIH COVID-19 Treatment Guidelines Panel January 6, 2021. As noted by the FLCCC:

“The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover.”

The FLCCC has also been calling for widespread adoption of ivermectin, both as a prophylactic and for the treatment of all phases of COVID-19. Ivermectin appears particularly promising as it binds to the spike protein compares to HCQ. 

India gave the best testimonio

India active COVID cases sit around 3.6 million on May17, 2021, according to the India Ministry of Health and Family Welfare. Mainstream media blamed the massive spike on a “scary, mutant variant” called B.1.617. The India health ministry updated its guidelines on April 28 for quarantines, treating the asymptomatic and those with mild symptoms of COVID-19. The agency now says that asymptomatic patients should “consider Tab Ivermectin (200 mcg/kg once a day, to be taken empty stomach) for 3 to 5 days.” Caregivers of patients in quarantine are instructed to “take Hydroxychloroquine prophylaxis as per protocol and as prescribed by the treating medical officer.” 

There are 292 studies (219 are peer-reviewed) proving the effectiveness of hydroxychloroquine as both a treatment and prophylaxis against COVID-19. Ivermectin has 93 studies (54 peer-reviewed) showing its effectiveness as treatment and prophylaxis against COVID-19. 

Miraculously, the main media stopped headline reporting on India suddenly as Coronavirus cases are plummeting in India thanks to new rules that promote Ivermectin and hydroxychloroquine to its massive population.

What prevent these efficient CCP virus treatment to be in use?

Just like HCQ, use of Ivermectin has been globally suppressed, discouraged and even warned against, despite decades of safe use for other ailments. This is the only legal way to bring experimental vaccines to the global marketplace, by proving that no effective treatments exist. This suppression of science on antiviral treatments has paved the way for emergency use authorization of experimental vaccines and forced countless patients to suffer (and die) on ventilators, without treatment.

Instead, Remdesivir is US top health official, Dr. Anthony Fauci’s favored drug to treat COVID-19. It is the first and only antiviral drug approved to treat COVID. Remdesivir is a virtual copy of Gilead’s HIV drug GS-7340/Tenofovir with a few slight changes. It is also a nucleoside/nucleotide reverse transcriptase inhibitor in the HIV retroviral drug class under Gilead’s GS-5734, which was tested in monkeys as an Ebola treatment, but was found effective against severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) in animal models.

In early 2020, Gilead began testing it for SARS-CoV-2 (CCP virus). The reverse transcriptase in it is “an enzyme in the human immunodeficiency virus (HIV) and many retroviruses that convert the RNA template to DNA,” according to research published in Molecule.

Gilead set a hefty price tag for its Remdesivir (trademark as Veklury, 100mg /$520 a vial for injection) $3120 per patient for a typical treatment course, for those with private insurance on June 29, 2020. Compare to the same treatment course of HCQ is usually less than $40 anywhere in the world.

But rather than protect public health and save lives using hydroxychloroquine, Ivermectin, et., Fauci promoted the ineffective, dangerous and expensive drug Remdesivir and COVID-19 gene therapies instead. It only tells that Fauci has a long history of corruption as a health authority.

The International Ivermectin for COVID Conference

April 24 through 25, 2021, Dr. Tess Lawrie hosted the first International Ivermectin for COVID Conference online. Twelve medical experts from around the world shared their knowledge during this conference, reviewing mechanism of action, protocols for prevention and treatment, including so-called long-hauler syndrome, research findings and real-world data. 

Had Ivermectin being employed in 2020 when medical colleagues around the world first alerted the authorities to its efficacy, millions of lives could have been saved, and the pandemic with all its associated suffering and loss brought to a rapid and timely end.

In her closing address, Dr. Lawrie stated: “The story of Ivermectin has highlighted that we are at a remarkable juncture in medical history. The tools that we use to heal and our connection with our patients are being systematically undermined by relentless disinformation stemming from corporate greed.” She proposed that doctors around the world join together to form a new people-centered World Health Organization.


Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (

Posted by: Malaca

More information, follow us

New York MOS Himalaya |GTV

New York MOS Himalaya |MOS TALK

New York MOS Himalaya |Twitter(EN)

New York MOS Himalaya |Twitter(CN)

New York MOS Himalaya |YouTube